Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis
NCT04756037Phase 3Completed
- Sponsor
- Sumitomo Pharma
- Start
- Mar 2021
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of relugolix + estradiol + norethindrone in pregnancy, sponsored by Sumitomo Pharma. Started Mar 2021; status: completed.
02
Drugs
relugolix + estradiol + norethindrone
03
Conditions
pregnancy
Beyond the preview
Go deeper on NCT04756037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04756037.